A recent study published in JAMA Network Open has shed light on the potential relationship between advanced breast cancer and cardiovascular disease (CVD) at the time of diagnosis. The findings suggest that individuals with advanced-stage breast cancer may have a higher likelihood of pre-existing CVD compared to those diagnosed with early-stage breast cancer.
This study not only highlights shared risk factors but also underscores the need for personalized screening approaches for patients with cardiovascular conditions.
The Connection Between Cancer and Cardiovascular Disease
Cancer and CVD are the two leading causes of mortality in the United States, sharing several well-established risk factors such as obesity, smoking, and sedentary lifestyles. Recent research indicates a potential direct causal link between these diseases.
In breast cancer, CVD can create an immunosuppressive environment, accelerating tumor growth and spread. Mechanistic studies have also found that conditions like cardiac remodeling, heart failure, and myocardial infarction (MI) can contribute to faster cancer progression.
About the Study
This case-control study analyzed data from Medicare-linked databases, focusing on female patients aged 66 and older diagnosed with invasive breast cancer between 2010 and 2019. The researchers explored whether pre-existing CVD was more prevalent in patients diagnosed with advanced-stage breast cancer.
Study Highlights:
- The cohort included 19,292 patients, with a median age of 73 years.
- Patients with CVD were identified based on diagnoses made 13-24 months before their breast cancer diagnosis to avoid concurrent diagnoses.
- The analysis compared patients with early-stage breast cancer (T1-T2, N0, M0) to those with advanced (T3-T4 or N+, M+) or metastatic (M+) breast cancer.
- Comorbidities, race, ethnicity, and receptor subtypes were factored into the analysis.
Key Findings
- Higher Odds of CVD in Advanced Breast Cancer
Patients diagnosed with metastatic or locally advanced breast cancer had statistically higher odds of pre-existing CVD. - Receptor Subtype Differences
The association was particularly strong in hormone receptor-positive breast cancer and ERBB2-negative (formerly HER2) subtypes. It was absent in hormone receptor-negative cases. - Shared Risks and Delayed Diagnosis
The association persisted even after accounting for shared risk factors and potential delays in breast cancer diagnosis. - Demographics
Most participants were White (86.5%) and non-Hispanic (94.5%), which limits the generalizability of the findings across more diverse populations.
Implications for Clinical Practice
This study underscores the importance of a multidisciplinary approach to managing patients with both breast cancer and cardiovascular disease.
Recommendations:
- Personalized Screening: Patients with pre-existing CVD may benefit from tailored screening approaches to detect cancer earlier.
- Collaborative Care: Cardiologists and oncologists should work together to manage shared risk factors and optimize patient outcomes.
- Education: Patients with CVD should be educated about the potential risks and symptoms of breast cancer to encourage timely screenings.
Limitations of the Study
While the findings are compelling, several limitations should be considered:
- The observational nature of the study does not establish causality.
- Potential misclassification of CVD using procedure codes.
- Important confounding factors, such as smoking and prior hormone replacement therapy, were not accounted for.
- The cohort primarily consisted of White patients, which may affect generalizability to other populations.
Conclusion
This study highlights a significant association between advanced-stage breast cancer and prevalent cardiovascular disease at diagnosis. Future research is needed to explore the benefits of personalized screening for individuals with CVD and further investigate the biological mechanisms linking these conditions.
By fostering collaboration between specialties and prioritizing patient education, we can address shared risks and improve outcomes for patients battling both breast cancer and cardiovascular disease.
To register for our next masterclass please click here https://linktr.ee/docpreneur
